Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD6621 |
| Synonyms | |
| Therapy Description |
AZD6621 is a T-cell engager targeting STEAP2, CD3, and CD8, which potentially induces activation of CD8-positive T-cells, STEAP2-dependent cytotoxicity, and inhibition of tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3514). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD6621 | AZD-6621|AZD 6621 | CD3 Antibody 119 | AZD6621 is a T-cell engager targeting STEAP2, CD3, and CD8, which potentially induces activation of CD8-positive T-cells, STEAP2-dependent cytotoxicity, and inhibition of tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 3514). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07192614 | Phase Ib/II | AZD6621 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC) | Recruiting | USA | 3 |